← FDA WARNING LETTERS
FDA WARNING LETTER21 July 2026

Alembic Pharmaceuticals Ltd. — FDA Warning Letter

In Vivo Bioavailability-Bioequivalence Studies – Clinical

Company
Alembic Pharmaceuticals Ltd.
Letter date
21 July 2026
Issuing office
Center for Drug Evaluation and Research (CDER)
READ THE FULL LETTER

The complete warning letter, including every cited observation, is published by the FDA. SPEQ surfaces and indexes it for reference — the authoritative text lives on fda.gov.

View on fda.gov →
DON’T BE THE NEXT LETTER
Assess your quality systemBaseline against 12 GxP domains in 10 minutes →Decode the standardsThe requirements behind the citations →All warning lettersBrowse the live FDA feed →

Warning-letter details are published by the U.S. FDA; SPEQ surfaces them for reference and is not affiliated with or endorsed by the FDA. The authoritative text is on fda.gov.